North Carolina: CARsgen Therapeutics Investment in Durham

Leading Cell Therapy Biotech Company Chooses Research Triangle for its North American R&D and Manufacturing Facility
CARsgen Therapeutics to invest $157 million and create 200 jobs in Durham

Raleigh, NC (STL.News) CARsgen Therapeutics Corporation, an innovative biotechnology company pursuing medicines to treat cancer will create approximately 200 jobs and invest $157 million in Durham, Governor Roy Cooper announced.  The company’s selection of the Research Triangle area will establish its first biomanufacturing site in North America.  CARsgen Therapeutics currently has its U.S. clinical development operations in Houston, Texas.

“Global companies know that North Carolina is a world class leader in biotechnology,” said Governor Cooper.  “Our state’s skilled workers, educational institutions and business environment provide life science companies with the tools they need to succeed.”

CARsgen Therapeutics Corporation, a wholly-owned subsidiary of CARsgen Therapeutics Holdings Limited, is a clinical stage biotechnology company specializing in what’s known as chimeric antigen receptor (CAR) T cell therapies, a type of therapy that engages people’s immune systems in a new way.  The therapeutic approach can yield medicines for various human cancers, including leukemia, lymphoma, and solid tumors.  The company’s project in North Carolina will establish a 37,000 square foot clinical/early-stage commercial manufacturing facility and then a 100,000 square foot cGMP commercial manufacturing facility in Durham that will eventually produce FDA approved cell therapies.

This News North Carolina: CARsgen Therapeutics Investment in Durham appeared first on STL.News.